Blue­print to pull Gavre­to in cer­tain mar­kets, shelve EGFR pro­grams as it fo­cus­es on Ay­vak­it launch

As Blue­print Med­i­cines braces it­self for a fu­ture with­out a ma­jor Roche col­lab­o­ra­tion, the Mass­a­chu­setts biotech is pulling its RET in­hibitor from cer­tain mar­kets and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER